| A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing. (NCT00733577) | GlaxoSmithKline | 2008-08-11 |
| Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose (NCT00741390) | Becton, Dickinson and Company | 2008-08-01 |
| A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione (NCT00743002) | OPKO Health, Inc. | 2008-08-01 |
| Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes (NCT00753181) | Abbott Nutrition | 2008-08-01 |
| Lifestyle Modification for Type 2 Diabetes Prevention in Overweight Youth (NCT01610219) | University of Pennsylvania | 2008-08-01 |
| A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate (NCT00740051) | Boehringer Ingelheim | 2008-08-01 |
| Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM (NCT00736099) | Boehringer Ingelheim | 2008-08-01 |
| A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise. (NCT00744926) | Hoffmann-La Roche | 2008-08-01 |
| A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin (NCT00734474) | Eli Lilly and Company | 2008-08-01 |
| A Randomized Controlled Trial of Exercise Training Among Men With Type 2-diabetes (NCT00666094) | Norwegian University of Science and Technology | 2008-08-01 |
| BI 10773 add-on to Metformin in Patients With Type 2 Diabetes (NCT00749190) | Boehringer Ingelheim | 2008-08-01 |
| The Effect of DBcare, a Food Supplement on Diabetes Control (NCT00563004) | Meir Medical Center | 2008-08-01 |
| Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM (NCT00929838) | State University of New York at Buffalo | 2008-08-01 |
| Guangzhou Nutrition and Health Study (GNHS) (NCT03179657) | Sun Yat-sen University | 2008-07-01 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (NCT00713830) | Sanofi | 2008-07-01 |
| A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. (NCT00717457) | Hoffmann-La Roche | 2008-07-01 |
| Comparison of Thrice Daily Biphasic Human Insulin With Basal Bolus Regimen in Type 2 Diabetes Mellitus Patients (NCT01039532) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2008-07-01 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (NCT00715624) | Sanofi | 2008-07-01 |
| Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics (NCT00697450) | Novo Nordisk A/S | 2008-07-01 |
| The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients (NCT00716092) | Boehringer Ingelheim | 2008-07-01 |
| A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide (NCT00696657) | Novo Nordisk A/S | 2008-06-03 |
| GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (NCT00707031) | Sanofi | 2008-06-01 |
| An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes (NCT00738153) | Novo Nordisk A/S | 2008-06-01 |
| Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes (NCT00698802) | Novo Nordisk A/S | 2008-06-01 |
| Production of Free Fatty Acids From Blood Triglycerides (NCT00911482) | Mayo Clinic | 2008-06-01 |
| Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes (NCT00699179) | Novo Nordisk A/S | 2008-06-01 |
| GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (NCT00712673) | Sanofi | 2008-06-01 |
| Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents (NCT00715780) | Novo Nordisk A/S | 2008-06-01 |
| Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%) (NCT00728351) | Novartis Pharmaceuticals | 2008-06-01 |
| The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus (NCT00700817) | Novo Nordisk A/S | 2008-06-01 |
| Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment (NCT00663260) | AstraZeneca | 2008-06-01 |
| Pioglitazone Incretin Study (NCT00656864) | University of Vermont | 2008-05-01 |
| Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control (NCT00701831) | Sanofi | 2008-05-01 |
| Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System (NCT00722241) | DexCom, Inc. | 2008-05-01 |
| Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes (NCT00737776) | Novo Nordisk A/S | 2008-05-01 |
| Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes (NCT01107171) | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2008-05-01 |
| Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes (NCT00704223) | Novo Nordisk A/S | 2008-05-01 |
| A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus. (NCT00682097) | Hoffmann-La Roche | 2008-05-01 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (NCT00688701) | Sanofi | 2008-05-01 |
| Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus (NCT00709475) | Novo Nordisk A/S | 2008-05-01 |
| Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes (NCT00690456) | Sanofi | 2008-05-01 |
| A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus (NCT01177163) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-05-01 |
| Immune Profile and Complication Risk in Type 2 Diabetes (NCT00674271) | University of Aarhus | 2008-05-01 |
| A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers (NCT00933530) | Sirtris, a GSK Company | 2008-05-01 |
| Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30 (NCT00675493) | Novo Nordisk A/S | 2008-05-01 |
| Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen® (NCT00709683) | Novo Nordisk A/S | 2008-05-01 |
| Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects (NCT00562250) | AstraZeneca | 2008-05-01 |
| Efficacy of Lubiprostone in Combination With Standard PEG Preparation (NCT00689026) | Augusta University | 2008-05-01 |
| Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health (NCT00679939) | GlaxoSmithKline | 2008-04-21 |
| Medication in Early Diabetes (MED) Study (NCT00437970) | Menzies School of Health Research | 2008-04-01 |
| Do Group Insulin Education Visits Reduce Barriers to Insulin Initiation? (NCT00645528) | US Department of Veterans Affairs | 2008-04-01 |
| Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin (NCT00693771) | Sanofi | 2008-04-01 |
| Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes (NCT00687063) | Novo Nordisk A/S | 2008-04-01 |
| Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (NCT00664534) | Eli Lilly and Company | 2008-04-01 |
| A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients (NCT00666718) | Eli Lilly and Company | 2008-04-01 |
| The TANTALUS® II for the Treatment of Type 2 Diabetes (NCT01303302) | MetaCure (USA), Inc. | 2008-04-01 |
| Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes (NCT00825643) | Novo Nordisk A/S | 2008-04-01 |
| Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus (NCT00637338) | Pfizer | 2008-04-01 |
| Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes (NCT00696163) | Novo Nordisk A/S | 2008-04-01 |
| A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus (NCT00630825) | Eli Lilly and Company | 2008-04-01 |
| A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes (NCT00675857) | Bellus Health Inc. - a GSK company | 2008-04-01 |
| Japanese P III vs Voglibose and Placebo (NCT00654381) | Boehringer Ingelheim | 2008-04-01 |
| PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients) (NCT00643474) | Hoffmann-La Roche | 2008-03-01 |
| Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes (NCT00735501) | Novo Nordisk A/S | 2008-03-01 |
| A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes (NCT01606397) | Eli Lilly and Company | 2008-03-01 |
| An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects (NCT00700648) | Novo Nordisk A/S | 2008-03-01 |
| Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2) (NCT00659477) | Sanofi | 2008-03-01 |
| Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir) (NCT00657930) | Novo Nordisk A/S | 2008-03-01 |
| A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide (NCT00671424) | GlaxoSmithKline | 2008-03-01 |
| Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes (NCT00729898) | Novo Nordisk A/S | 2008-03-01 |
| Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone (NCT00641043) | Boehringer Ingelheim | 2008-03-01 |
| A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes (NCT00674986) | Hoffmann-La Roche | 2008-03-01 |
| Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin (NCT00676741) | Novo Nordisk A/S | 2008-02-01 |
| Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes (NCT00622284) | Boehringer Ingelheim | 2008-02-01 |
| Supplements for Controlling Resistance to Insulin (NCT00699413) | University of Southern California | 2008-02-01 |
| Effect of PF-00734200 in Subjects With Type 2 Diabetes (NCT00618007) | Pfizer | 2008-02-01 |
| The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus (NCT00620282) | Novo Nordisk A/S | 2008-02-01 |
| Glufast On Insulin Glargine Trial in Type 2 DM (NCT00663884) | JW Pharmaceutical | 2008-02-01 |
| An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment (NCT00698269) | Novo Nordisk A/S | 2008-02-01 |
| BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes (NCT00602472) | Boehringer Ingelheim | 2008-02-01 |
| Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control (NCT00621140) | Boehringer Ingelheim | 2008-02-01 |
| Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus (NCT00687284) | Novo Nordisk A/S | 2008-02-01 |
| Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus (NCT00655200) | Novo Nordisk A/S | 2008-02-01 |
| Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes (NCT00633997) | Novartis | 2008-02-01 |
| Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes (NCT00660374) | Novo Nordisk A/S | 2008-02-01 |
| Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes (NCT00627445) | Novo Nordisk A/S | 2008-02-01 |
| A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus (NCT00642538) | Mannkind Corporation | 2008-02-01 |
| A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015) (NCT00631488) | Merck Sharp & Dohme LLC | 2008-02-01 |
| Improving the Care of Diabetic Patients: A Randomized Trial of a Family Physician Office-Based Chronic Disease Care Model for Patients With Type 2 Diabetes (NCT00789282) | University of Alberta | 2008-02-01 |
| Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (NCT00634842) | Novo Nordisk A/S | 2008-02-01 |
| A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects (NCT00625859) | GlaxoSmithKline | 2008-01-16 |
| Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects (NCT00615212) | GlaxoSmithKline | 2008-01-02 |
| 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes (NCT00558571) | Boehringer Ingelheim | 2008-01-01 |
| Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes (NCT00700765) | Novo Nordisk A/S | 2008-01-01 |
| Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes (NCT00614055) | Novo Nordisk A/S | 2008-01-01 |
| Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes (NCT00700830) | Novo Nordisk A/S | 2008-01-01 |
| Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes (NCT00601250) | Boehringer Ingelheim | 2008-01-01 |
| Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide (NCT00745433) | Novo Nordisk A/S | 2008-01-01 |
| Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes (NCT00704574) | Novo Nordisk A/S | 2008-01-01 |
| Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes (NCT00692237) | University of Roma La Sapienza | 2008-01-01 |